Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Guillain-Barre Syndrome
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(107)
•••
Post by prophetoffactzon May 22, 2023 8:05am
312 Views
Post# 35458897

Guillain-Barre Syndrome

Guillain-Barre SyndromeBTI lists the market at an expected US$679.6 million in 2027.

Considering the growing number of individuals vaccinated for COVID-19 worldwide, such reports of GBS will increase in the near future.

From the data that can be looked up, the incidence of GBS following SARS-CoV-2 infection fluctuated from 0.12 per 100,000 person-years to 9.44 per 100,000 person-years [6, 8], while after receiving the Ad.26.COV2.S (Janssen) vaccine was 32.4 per 100 000 person-years [50]. It seemed that people were more susceptible to be GBS when vaccinated, actually, the data about GBS related to vaccinations are incomplete [57]. Therefore, it is hard to compare the rate of GBS after SARS-COV-2 infection and after COVID-19 vaccination reasonably.
Is there a causal nexus between COVID-19 infection, COVID-19 vaccination, and Guillain-Barr syndrome? | European Journal of Medical Research | Full Text (biomedcentral.com)
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities